Research summary

5-Amino-1MQ research

A small molecule inhibitor of NNMT (nicotinamide N-methyltransferase) studied for metabolic regulation and adipose tissue browning effects.

Metabolic Small MoleculeSmall molecule NNMT inhibitorMW159.21 g/mol (cation) / 286.11 g/mol (iodide salt)CAS42464-96-0StatusNot FDA-approvedNCAANot listed

Evidence at a glance

What the research says about 5-Amino-1MQ

The 5-Amino-1MQ evidence base cited here is 8 sources — 8 preclinical. Critically, that evidence is almost entirely preclinical (animal and in-vitro) — no human clinical trials are cited, so efficacy and safety in people remain unproven. Regulatory status: Not FDA-approved.

Summary

Key takeaways

  • 5-Amino-1MQ is a small molecule (not a peptide) that inhibits the enzyme NNMT (nicotinamide N-methyltransferase), which in turn helps preserve cellular NAD+ and supports mitochondrial and metabolic function.
  • It is taken orally; reported animal data put oral bioavailability around 38% with an oral half-life near 7 hours.
  • The most-cited findings are improved muscle function and grip strength in aged mice and modest fat loss in obese-mouse models — promising, but a long way from established human benefit.

Overview

5-Amino-1MQ (5-amino-1-methylquinolinium) is a research compound studied for metabolism and longevity. Mechanistically it is an inhibitor of NNMT, an enzyme that consumes the NAD+ precursor pathway; by blunting NNMT it is proposed to raise or preserve cellular NAD+ and, through that, support mitochondrial function, energy metabolism, and possibly fat metabolism.

What Is 5-Amino-1MQ?

It is a small-molecule, orally available inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT methylates nicotinamide (a precursor in the NAD+ salvage pathway); over-activity of NNMT is associated with depleted NAD+ and metabolic dysfunction in fat and muscle tissue. Inhibiting the enzyme is the lever 5-Amino-1MQ is designed to pull.

How It Works

NNMT inhibition → NAD+ preservation

By inhibiting NNMT, 5-Amino-1MQ is proposed to reduce wasteful methylation of nicotinamide and keep more substrate available for NAD+ synthesis, supporting the NAD+-dependent enzymes (sirtuins, PARPs) tied to energy metabolism and cellular repair.

Mitochondrial & metabolic support

Higher NAD+ availability is associated in preclinical work with improved mitochondrial efficiency, reduced oxidative stress, and — in fat tissue — a shift toward energy expenditure, which is the basis for the longevity and body-composition interest. These are mechanistic hypotheses supported by animal data, not demonstrated human outcomes.

Pharmacokinetics (preclinical)

  • Oral bioavailability ~38% (rat data)
  • Time to peak: roughly 48 minutes
  • Half-life: ~7 hours oral (≈3.8 hours IV in rats); largely cleared within ~1.7 days

All pharmacokinetic figures are from animal studies. Human PK has not been characterized.

Research Findings (preclinical)

  • Rat pharmacokinetic study (2021): established the ~38% oral bioavailability and oral/IV half-lives.

These are animal results. They motivate human research but do not establish that 5-Amino-1MQ works — or is safe — in people.

Safety

Storage & Quality

  • Store cool and dry, away from light and moisture.
  • Quality indicators: uniform white-to-off-white capsules/powder, sealed packaging, and a third-party COA showing >98% purity with heavy-metals testing.
  • Warning signs: moisture damage, clumping or stickiness, discoloration, or a strong chemical odor (possible contamination or degradation).

Citations

8 peer-reviewed sources

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.

Related research

More compounds to explore

Failed to fetch